COVID-19 is once again reemerging across various countries in Asia, this time driven by a rapidly spreading Omicron subvariant—JN.1.
This new strain was first identified in the United States in August 2023 and, within a few months, spread to more than 120 countries. The World Health Organization (WHO) declared it a "Variant of Interest" in December last year.
Currently, JN.1 has become the most prevalent COVID strain globally. Research shows that in April 2024, 94% of all COVID samples contained this variant. The virus has undergone around 30 genetic mutations, making it significantly more contagious.
In India, the situation remains under control. As of May 19, only 257 active cases have been reported, mostly in the states of Kerala, Maharashtra, and Tamil Nadu.
While cases had once surpassed a thousand in January, the numbers have dropped considerably. Authorities report that most patients are experiencing mild symptoms and have not required hospitalization.
People are being advised to stay cautious by wearing masks, washing hands, and keeping vaccinations up to date.
Meanwhile, the situation is relatively worse in Singapore and Hong Kong. In Singapore, weekly infections have risen from 11,000 to over 14,000.
In Hong Kong, 81 severe cases and 30 deaths have been reported, most of them among the elderly and those with pre-existing health conditions.
Common symptoms of JN.1 infection include dry cough, mild fever, sore throat, fatigue, loss of taste or smell, and, in some cases, digestive issues. However, experts say current vaccines—particularly mRNA, viral vector, and protein subunit vaccines—continue to offer effective protection against this variant.
The WHO has stated that JN.1 has not posed any significant new public health risk so far. Still, given its high transmissibility, it should not be taken lightly. Doctors and researchers agree that public awareness, adherence to hygiene protocols, and vaccination remain the strongest tools to combat this variant.
